PRKD1 and neoplasm: Moreover, miR-34a can target PRKD1 to overcoming cancer stemness and drug resistance in human breast (26) and hTERT promoter-driven VISA delivery of miR-34a (TV-miR-34a) can significantly inhibit the tumor-initiating properties of long-term-cultured BCSC in vitro and reduced the proliferation of BCSC in vivo (29).